FDA revises compliance guide on pre-approval inspections - raps.org
FDA has revised its compliance guide on pre-approval inspections, which may affect how manufacturers prepare for and undergo inspections before drug approval.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that are subject to FDA pre-approval inspections. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the change text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA updated its compliance guide on pre-approval inspections, potentially altering expectations and procedures for these inspections.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that are subject to FDA pre-approval inspections.
What you must do
Review the revised compliance guide to understand any new or changed expectations for pre-approval inspections and adjust internal inspection-readiness practices accordingly.
Deadline
Not specified in the change text.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- This Week at FDA: Antibiotic impurities guidance, new nitrosamine woes, and FDA’s busy calendar - RAPS
- “Hub-and-spoke” drug manufacturing set to benefit from new FDA rule - finance.yahoo.com
- After five years of attempts, Virginia on track to set up a Prescription Drug Affordability Board - virginiamercury.com
- August 29, 2022: FDA warns “Tramadol US” to stop selling controlled, unapproved drugs to U.S. residents - Partnership for Safe Medicines
- Toward Better-Quality Compounded Drugs — An Update from the FDA - nejm.org